EVAX
Evaxion A/S American Depositary ShareEVAX
EVAX
About: Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
Employees: 46
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
267% more capital invested
Capital invested by funds: $682K [Q4 2024] → $2.5M (+$1.82M) [Q1 2025]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 [Q4 2024] → 10 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
1.02% less ownership
Funds ownership: 1.45% [Q4 2024] → 0.43% (-1.02%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
405%
upside
Avg. target
$14
405%
upside
High target
$14
405%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 405%upside $14 | Buy Reiterated | 2 Apr 2025 |
Financial journalist opinion
Based on 6 articles about EVAX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Evaxion receives grant funding to design new polio vaccine
COPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives funding support from the Gates Foundation to help the world eradicate polio (poliomyelitis) by exploring design options for a new and unique vaccine.
Neutral
Seeking Alpha
2 weeks ago
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast.
Neutral
GlobeNewsWire
2 weeks ago
Evaxion announces business update and first quarter 2025 financial results
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results.
Positive
Seeking Alpha
2 weeks ago
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments).
Neutral
GlobeNewsWire
3 weeks ago
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.
Neutral
GlobeNewsWire
3 weeks ago
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
Neutral
GlobeNewsWire
1 month ago
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting
COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data underscoring the ability of cancer vaccine EVX-01 to drive a targeted and robust immune response. Designed with Evaxion's AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
Neutral
GlobeNewsWire
2 months ago
Evaxion to present at World Vaccine Congress
COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.
Neutral
Seeking Alpha
2 months ago
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Swayampakula Ramakanth - HCW Operator Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.
Neutral
GlobeNewsWire
2 months ago
Evaxion to announce business update and full year 2024 financial results on April 1, 2025
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.
Charts implemented using Lightweight Charts™